Hikma Pharmaceuticals ( (GB:HIK) ) just unveiled an update.
Hikma Pharmaceuticals reported a strong financial performance for 2024, with a 10% growth in core revenue and a 67% increase in reported operating profit. The company’s strategic acquisitions, such as Xellia Pharmaceuticals’ US business, and new partnerships have bolstered its market position, particularly in the injectables and generics segments. Hikma’s continued investment in R&D and business development is expected to drive future growth, with a positive outlook for 2025, including projected revenue growth of 4% to 6%. The company’s robust balance sheet and increased dividend reflect confidence in its future prospects.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a global pharmaceutical company headquartered in the UK, specializing in high-quality branded and non-branded generic medicines. With a significant presence in North America, the Middle East, North Africa, and Europe, Hikma is a leading supplier of generic medicines and injectable products. The company focuses on transforming cutting-edge science into innovative solutions, supporting a healthier world through its diverse product portfolio and strategic partnerships.
YTD Price Performance: 15.60%
Average Trading Volume: 417,757
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £5.11B
Learn more about HIK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com